The questions patients ask quietly — and what an honest, medically grounded answer looks like.
It’s one of the most common thoughts people have in psychiatric care, and one of the least often voiced out loud.
What if I tried coming off this medication?
Sometimes it comes from a good place — feeling stable, wondering if the support is still needed, wanting to know who you are without the medication you’ve been taking for years. Sometimes it comes from frustration — side effects that have accumulated quietly, a sense of emotional flatness, a feeling of being not quite yourself. Sometimes it’s practical — a pregnancy, a new job, a change in insurance, a life that looks different enough now that the old plan deserves a fresh look.
Whatever the reason, the question deserves a real answer. Not a reflexive renewal of the prescription. Not a dismissive “you need this medication” without examining whether that’s still true. And not a panicked internet deep-dive that ends in stopping cold turkey and wondering why everything fell apart.
Coming off psychiatric medication is a legitimate clinical goal for many patients. It’s also something that goes wrong often enough, and in predictable enough ways, that it’s worth understanding before you try it.
Why this conversation is harder than it should be
The honest reason most patients don’t raise this question with their psychiatrist is that they expect it to go badly. They expect to be told no. They expect a short visit to get even shorter. They expect to feel like a difficult patient for asking.
Sometimes that expectation is unfair to the clinician. But sometimes it’s accurate — the psychiatric system that produces the ultra-short visits doesn’t leave much room for the nuanced conversation that deprescribing requires.
The result is that patients sometimes stop medications on their own, without guidance, and run into problems that were entirely predictable and largely preventable. Or they stay on medications indefinitely, not because anyone has assessed whether they’re still needed, but because stopping never came up and inertia is powerful.
Neither outcome is good medicine.
The difference between withdrawal and relapse
This is the most important distinction in the whole conversation, and it’s the one that most often gets blurred.
When someone stops a psychiatric medication and feels worse, there are two fundamentally different things that could be happening. One is a withdrawal or discontinuation syndrome — the brain’s reaction to the abrupt removal of a substance it has adapted to. The other is a return of the underlying condition the medication was treating.
These feel similar from the inside. They can even look similar from the outside. But they’re different in important ways, and the right response to each is different.
Discontinuation syndrome typically starts within days of stopping or significantly reducing the medication, peaks in the first one to two weeks, and gradually resolves. The symptoms depend on the medication — SSRIs and SNRIs are the most common culprits — but can include dizziness, flu-like symptoms, irritability, heightened anxiety, insomnia, and the distinctive “brain zaps” that people who have experienced them describe as brief electrical sensations in the head. Paroxetine and venlafaxine have some of the most pronounced discontinuation effects; fluoxetine, with its very long half-life, tends to produce much milder ones.
Relapse typically takes longer to develop, usually weeks to months rather than days. The symptoms resemble the original condition rather than a flu. And crucially, relapse doesn’t resolve on its own — it tends to deepen if untreated.
A medically supervised taper allows these two possibilities to be distinguished clearly, at a pace slow enough to tell which one is happening and respond accordingly. Stopping abruptly collapses the timeline in a way that makes the distinction nearly impossible.
What a safe taper actually looks like
The general principle is simple: slower is better, and the end is harder than the beginning.
Most psychiatrists taper psychiatric medications by reducing the dose in increments, with observation periods between reductions to assess how the patient is responding. The pace depends on the specific medication, the dose, how long the patient has been taking it, their history with discontinuation, their current stability, and the clinical context.
For SSRIs and SNRIs, common tapering schedules reduce by roughly ten percent of the current dose every two to four weeks, with slower reductions as the dose gets lower. This reflects an important but counterintuitive reality: the last small doses are pharmacologically more significant than the larger ones earlier in the taper. The difference between 20mg and 10mg of an SSRI affects the brain differently than the difference between 100mg and 90mg. Going too fast at the low end is where most people run into trouble.
Benzodiazepines for example require particular care and typically much longer tapers — months to years in cases of long-term use. Abrupt discontinuation of benzodiazepines in dependent patients can cause seizures and is a medical emergency. This is one of the clearest cases where “I’ll just stop” is genuinely dangerous rather than merely inadvisable.
Mood stabilizers and antipsychotics have their own considerations, often including the risk of rebound symptoms that can look like — and sometimes trigger — the conditions they were treating.
None of this is meant to be frightening. It’s meant to explain why the specific medication, dose, duration of use, and clinical history all matter — and why a taper that worked smoothly for one person on one medication might be entirely wrong for someone else.
When stopping is the right decision
Deprescribing isn’t the right move for everyone at every stage of care. But it’s the right move more often than the current system tends to acknowledge.
Good candidates for a trial of tapering often include patients who have been stable for an extended period — typically at least six to twelve months for depression — and whose lives are in a relatively settled phase. Patients who achieved stability in part because of significant life changes alongside the medication — therapy, relationship changes, sleep, exercise, reduced stress — often maintain that stability better than those for whom nothing else changed. Patients whose original episode was a first episode and whose recovery has been complete are statistically more likely to remain well off medication than those with multiple prior episodes.
A careful reassessment also sometimes finds that patients are on medications that were added during a difficult period and never revisited — a sleep aid from a hospitalization three years ago, an anxiolytic prescribed by a different doctor, an augmenting agent added when a prior antidepressant wasn’t fully working and never removed when the next one did. Each of those may have been reasonable when added. None of them may still be earning its place in the regimen.
When it isn’t
Timing matters enormously. There are situations where a trial of tapering is inadvisable regardless of how stable the patient feels.
Active major stress — a job loss, a divorce, a medical diagnosis, a significant loss — is one of the most common reasons to pause a planned taper. The medication is doing work during that period even if the patient doesn’t feel like they’re struggling, and removing it adds vulnerability at a moment of increased demand.
Recent instability — a depressive episode, a hospitalization, a period of significantly worsened symptoms within the last six to twelve months — is generally a signal to wait longer before trying.
Multiple prior episodes increase the statistical risk of recurrence off medication, and that risk should be named honestly. For someone who has had three or more depressive episodes, the conversation about stopping medication is different from the conversation with someone who had a first episode two years ago and has been stable since.
Certain conditions — bipolar disorder, recurrent psychosis, severe OCD — carry higher risks with medication discontinuation and require more conservative approaches.
None of this is a permanent no. It’s a question of timing, preparation, and informed decision-making.
The role of a psychiatrist who actually has time
This is where the systemic problem becomes a clinical one.
A careful deprescribing conversation requires time. It requires reviewing the full medication history, the original reasons for each prescription, what was happening in the patient’s life when each medication was added, how the patient has responded to prior changes, what the patient’s goals actually are, and what the realistic risks and benefits of proceeding look like for this specific person in their current life.
That conversation may not happen in ultra-short visit alongside a prescription renewal. Which means it often doesn’t happen at all — and patients are left carrying medications indefinitely not because the decision was made consciously, but because the decision was never made.
A psychiatrist who approaches deprescribing seriously will also build in monitoring — regular check-ins during the taper, clear criteria for what would prompt slowing down or pausing, a plan for what to do if symptoms return, and a shared understanding that stopping a medication and later deciding to restart it is not a failure. It’s information.
The takeaway
If you’ve been wondering whether you still need the medication you’re taking — or whether all of it is still necessary — that’s a question worth raising out loud with a clinician who will take it seriously.
The answer may be yes, you still need it, and here’s why. Or it may be that a thoughtful trial of tapering is appropriate, and here’s how we’d do it safely. Or it may be that the timing isn’t right yet, but here’s what we’d want to see before trying.
What the answer shouldn’t be is a reflexive renewal without a real conversation.
Psychiatric medications are tools. The goal was never to be on them indefinitely — it was to feel better, function well, and live the life you want to live. Sometimes that means staying on medication long-term, and that’s a legitimate outcome. Sometimes it means carefully, thoughtfully finding out whether you still need it.
Both deserve to be treated as real clinical questions.
Goldstone Psychiatry & Neuromodulation Center offers modern, personalized psychiatric care — including thoughtful medication review, simplification, and supervised deprescribing for patients who want to reassess their regimen. Telepsychiatry is also available throughout Texas.
No comment